Vaccinex Inc (VCNX)

Vaccinex Inc. is a clinical-stage biotechnology company listed on OTC Markets under the ticker VCNX. The company focuses on developing targeted biotherapeutics for cancer, neurodegenerative conditions, and autoimmune diseases. Its lead program, pepinemab, is a humanized monoclonal antibody designed to inhibit SEMA4D activity and is being studied in several mid-stage clinical programs, including Alzheimer’s disease, Huntington’s disease, and multiple cancer indications such as head and neck cancer, pancreatic cancer, non-small cell lung cancer, melanoma, and breast cancer. Vaccinex is also advancing its ActivMAb antibody discovery platform, along with CHS-114, an anti-CCR8 antibody, and VX5, which is in preclinical development for autoimmune-related disorders. The company maintains collaborations with Merck Sharp & Dohme, Ares Trading S.A., Emory University, the Huntington Study Group, Catalent Pharma Solutions, and Surface Oncology. Founded in 2001, Vaccinex is headquartered in Rochester, New York.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.